Ironwood Pharmaceuticals, Inc.
IRWD
$4.31
$0.235.64%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 113.04M | 106.51M | 47.71M | 122.06M | 85.24M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 113.04M | 106.51M | 47.71M | 122.06M | 85.24M |
| Cost of Revenue | 22.42M | 21.94M | 21.86M | 22.47M | 23.37M |
| Gross Profit | 90.62M | 84.57M | 25.85M | 99.59M | 61.87M |
| SG&A Expenses | 11.31M | 12.03M | 19.10M | 21.91M | 16.80M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 33.73M | 33.97M | 40.96M | 44.38M | 40.17M |
| Operating Income | 79.31M | 72.53M | 6.75M | 77.68M | 45.07M |
| Income Before Tax | 73.73M | 65.17M | 455.00K | 68.02M | 37.82M |
| Income Tax Expenses | 22.44M | 24.40M | 2.73M | 27.94M | 14.22M |
| Earnings from Continuing Operations | 51.29M | 40.77M | -2.28M | 40.08M | 23.60M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 51.29M | 40.77M | -2.28M | 40.08M | 23.60M |
| EBIT | 79.31M | 72.53M | 6.75M | 77.68M | 45.07M |
| EBITDA | 79.76M | 72.98M | 7.21M | 78.16M | 45.54M |
| EPS Basic | 0.31 | 0.25 | -0.01 | 0.25 | 0.15 |
| Normalized Basic EPS | 0.28 | 0.25 | 0.00 | 0.27 | 0.15 |
| EPS Diluted | 0.31 | 0.24 | -0.02 | 0.23 | 0.14 |
| Normalized Diluted EPS | 0.28 | 0.24 | 0.00 | 0.25 | 0.13 |
| Average Basic Shares Outstanding | 164.41M | 163.45M | 162.44M | 162.22M | 161.72M |
| Average Diluted Shares Outstanding | 167.18M | 166.69M | 162.44M | 177.76M | 176.84M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |